Francois Cedric

CIK 00016580801 companyWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001658080

Recent Transactions

50 trades

Gift
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-03-11−64,869→ 425,968 total
Gift
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-03-11+64,869→ 372,815 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-02-03$3.76/sh+8,840→ 490,837 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2026-02-03−8,840→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-28+195,952→ 481,997 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-22$21.77/sh−27,192→ 286,045 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-20$19.79/sh−8,182→ 313,237 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-08-28$28.39/sh−49,963→ 307,946 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-08-27$28.19/sh−175,037→ 357,909 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-07-17−8,997→ 100,538 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-07-17$4.31/sh+8,997→ 351,330 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-07-17$20.21/sh−19,725→ 331,605 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-07-15$4.31/sh+800→ 344,233 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-07-15$20.09/sh−1,900→ 342,333 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-07-15−800→ 109,535 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-07-14$20.19/sh−137,465→ 343,433 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-07-14−65,203→ 110,335 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-07-14$4.31/sh+65,203→ 480,898 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-06-09$19.39/sh+287,500→ 287,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-29$29.52/sh−2,824→ 415,695 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-22$30.43/sh−13,551→ 418,519 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-21+130,662→ 432,070 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-17$29.96/sh−6,007→ 301,408 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-13$28.70/sh−6,247→ 307,415 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-11-01−182,146→ 472,065 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-03-01−200,000→ 175,538 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$62.96/sh−41,704→ 493,090 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$65.68/sh−413→ 313,662 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$64.92/sh−116,512→ 314,075 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$3.76/sh+50,000→ 363,662 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$64.26/sh−62,503→ 430,587 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$62.21/sh−28,868→ 534,794 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-03-01−50,000→ 8,840 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-01$4.31/sh+200,000→ 563,662 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-02-12$67.77/sh−3,962→ 313,662 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-29$64.14/sh−2,843→ 317,624 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-22$65.00/sh−13,431→ 320,467 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16$66.81/sh−7,851→ 333,898 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-16$66.30/sh+104,834→ 104,834 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16+72,094→ 341,749 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-21$48.80/sh−5,000→ 269,655 total
Gift
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-19−150,000→ 274,655 total
Gift
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-19+150,000→ 804,211 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-01$42.44/sh−10,284→ 424,655 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-09-01−300,000→ 0 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-01$41.70/sh−139,716→ 434,939 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-01$2.67/sh+300,000→ 574,655 total
Gift
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-05-24+20,000→ 654,211 total
Gift
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-05-24−20,000→ 274,655 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-05-17−20,000→ 300,000 total

Companies

Apellis Pharmaceuticals, Inc.
Director, Chief Executive Officer
$APLS

Recent Filings

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451

View on SEC.gov